RT Journal Article
SR Electronic
T1 Timeliness of provisional U.S. mortality data releases during the COVID-19 pandemic: delays are associated with electronic death registration system and weekly mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.07.21249401
DO 10.1101/2021.01.07.21249401
A1 Rosenbaum, Janet E.
A1 Stillo, Marco
A1 Graves, Nathaniel
A1 Rivera, Roberto
YR 2021
UL http://medrxiv.org/content/early/2021/03/28/2021.01.07.21249401.abstract
AB All-cause mortality counts allow public health authorities to identify populations experiencing excess deaths from pandemics, natural disasters, and other emergencies. Further, delays in the completeness of mortality counts may contribute to misinformation because death counts take weeks to become accurate. We estimate the timeliness of all-cause mortality releases during the Covid-19 pandemic for the dates April 3-September 5, 2020 by estimating the number of weekly data releases of the NCHS Fluview Mortality Surveillance System until mortality comes within 99% of the counts in the March 19, 2021 provisional mortality data release. States’ mortality counts take 5 weeks at median (interquartile range 4--7 weeks). The fastest states were Maine, New Hampshire, Vermont, New York, Utah, Idaho, and Hawaii. States that hadn’t adopted the electronic death registration system (EDRS) were 4.8 weeks slower to achieve complete mortality counts, and each weekly death per hundred million (range 1-10, median 2) was associated with a 0.8 week delay. Emergency planning should improve the timeliness of mortality data by improving state vital statistics digital infrastructure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received to support this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is an analysis of publicly available data from United States federal sources in broad categories such that individuals cannot be identified, so it is not human subjects research and is exempt from requiring human subjects board review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will post the raw data and code on a public repository.